Aspreva Pharmaceuticals believes that bad aim can be a good thing when treating diseases. This company conducts clinical trials to find new uses for approved drugs. As a result, partners team up with Aspreva to gain incremental revenue from the commercialization of the new version of the drug. Working in collaboration with Roche, Aspreva conducts clinical trials to investigate the use of Roche's CellCept (indicated for prevention of rejection in organ transplant patients) to treat autoimmune diseases including lupus nephritis and pemphigus vulgaris. Aspreva is a subsidiary of Swiss pharmaceutical firm Galenica Group.

MWG-Biotech is doing its part to help decode the world's most complicated and delicate language: the genome. The company has developed a highly sophisticated system of gene sequencing, analysis and genotyping, as well as applying those analyses to replacement, alteration, and synthesis of RNA and oligonucleotides. Its automated laboratories can carry out tasks in less than two days. The company performs its sequencing work at production sites in Germany, India, and the US.

Tetracore, Inc. company's FDA-approved Redline lab test can distinguish anthrax bacteria from similar microorganisms. Other bioterrorism countermeasures the firm offers include the BioThreat Alert testing kit used by first responders to detect various biological toxins including botulinum toxin (botulism) and staphylococcus aureus enterotoxin B (SEB). Tetracore also sells veterinary diagnostic (VetAlert) tests for foot-and-mouth disease, West Nile, and other diseases, and it markets antibodies (proteins) for use by research labs.

Avexa discovers drugs to treat vexing ailments. The pharmaceutical and research company works on the discovery and development of drugs for the treatment of infectious diseases, specifically HIV and antibiotic-resistant strains of bacteria. Avexa has worked on collaborative projects with Victorian College of Pharmacy, The Shanghai Institute of Organic Chemistry, North Carolina State University, and Georgetown University, among other institutions. The company was formed in 2004 when it was spun off from Australian drug discovery and biotechnology development company Amrad. Plans to merge with drugmaker Progen Pharmaceutical were canceled in 2009.

SkinMedica, Inc. was founded in 1999 and is headquartered in Carlsbad, California. SkinMedica, Inc. operates as a specialty pharmaceutical company that focuses on developing, acquiring, and commercializing products that treat dermatologic conditions and diseases and enhances the appearance of skin. It offers gels for the treatment of mild to moderate atopic dermatitis; creams for the reduction in growth of unwanted facial hair in women; franchises for the treatment of acne; and products for the treatment of hyperpigmentation. The company also provides anti aging products, aesthetic skin care, moisturizers, and sun protection, eye products, as well as facial and sensitive skin cleansers, rejuvenative and acne treatment toners, and skin polishers. It markets and sells prescription pharmaceutical products, and physician-dispensed and non-prescription skin care products primarily to dermatologists and pediatricians.

Nektar Therapeutics company was founded in 1990 and is headquartered in San Carlos, California. Nektar Therapeutics is a biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and advanced polymer conjugate technology platforms, which are designed to improve the benefits of drugs for patients. The Company’s product pipeline is comprised of drug candidates across a number of therapeutic areas including oncology, pain, anti-infectives, anti-viral and immunology. Nektar’s research and development activities involve small molecule drugs, peptides and other potential biologic drug candidates. It creates its drug candidates by using its chemistry platform to modify the chemical structure of drugs using polymer conjugates. Nektar’s drug candidates are designed to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability, metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient.

Eurand N.V. company was formerly known as Eurand B.V. Eurand N.V. was incorporated in 1984 and is based in Amsterdam, the Netherlands. Eurand N.V., a specialty pharmaceutical company, develops, manufactures, and commercializes pharmaceutical and biopharmaceutical products. The company develops these products based on its proprietary customized release technologies used to reduce daily dosing requirements and time the release of drugs in the body to increase efficacy or to reduce side effects; Tastemasking/ODTs technologies to increase patient compliance through more convenient dosage forms, such as orally disintegrating tablets and taste-masked drugs; bioavailability enhancement technologies to improve drug absorption; and drug conjugation technologies to extend drug half-life and to target specific organs or other biological targets, such as tumors. Its technologies are used for applications in drug products used for various therapeutic areas, including cardiovascular, gastrointestinal, pain, nutrition, and respiratory.Eurand company offers EUR-1037, as an over-the-counter sleep-aid; EUR-1025, an oral formulation of ondansetron, an anti-emetic prescribed to prevent nausea and vomiting; and EUR-1073, an enteric coated, controlled release formulation of beclomethasone diproprionate for the treatment of inflammatory bowel disease. It products also include Zentase, also known as EUR-1008, a porcine-derived proprietary enzyme replacement product for the treatment of exocrine pancreatic insufficiency, which has completed Phase III clinical trials; Amrix, a sustained release formulation of cyclobenzaprine hydrochloride, used as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute and painful musculoskeletal conditions; and products and services to the cystic fibrosis community.

Tongjitang Chinese Medicines Company was founded in 1995 and is headquartered in Shenzhen, the People's Republic of China. Tongjitang Chinese Medicines Company, through its subsidiaries, engages in the development, manufacture, marketing, and sale of Chinese medicines, nutritional products, and Tibetan recipe-originated plant-based medicines in the People’s Republic of China. The company also involves in the wholesale and retail of medicines. It offers Xianling Gubao for the treatment of osteoporosis, osteoarthritis, ischemic bone necrosis, and bone fractures; Zaoren Anshen Capsules for the treatment of insomnia; and moisturizing and anti-itching Capsules for the treatment of inflammatory skin conditions. The company also produces and sells Dianbaizhu Syrup for the treatment of vertigo; Compound Glycyrrhiza oral solution for the treatment of upper respiratory infections; Jiao Ti Guo Jiao Bi Capsules that prevent gastritis and ulcers; Bu Shen Yi Lao capsules, which improve memory, breathing, hearing, and general malaise; Xin Nao Kang capsules for the treatment of stroke and coronary artery disease; Jincishen Mixture used as an ancillary to treatment of cancer; Heiguteng capsules for the treatment of rheumatoid arthritis; Chongcao Qingfei capsules for the treatment of Chronic Obstructive Pulmonary Disease; Fengshi Gutong capsules for the treatment of rheumatoid arthritis; and Jingshu Granules for treatment of degenerative osteoarthritis. In addition, its product pipeline candidates comprise Jing Tong Ting, a phase III clinical trial product for menstrual pain; Da An Granules, a phase III ongoing product for anxiety; Yushuda Tablets, a phase III ongoing product for depression; and Dan Xian Kang Gu Capsules, a phase III design ongoing product for ischemic necrosis.

ARYx Therapeutics, Inc. was incorporated in 1997 and is based in Fremont, California. ARYx Therapeutics, Inc., a biopharmaceutical company, focuses on developing a portfolio of product candidates designed to eliminate known safety issues associated with commercial drugs using its RetroMetabolic Drug Design technology. Its product portfolio includes tecarfarin, an oral anticoagulant in Phase II/III clinical development for the treatment of patients who are at risk for the formation of dangerous blood clots; budiodarone/ATI-2042, an oral antiarrhythmic agent in Phase II clinical development for the treatment of atrial fibrillation, a form of irregular heartbeat; ATI-7505, an oral prokinetic agent in Phase II clinical development for the treatment of chronic constipation, gastroparesis, functional dyspepsia, irritable bowel syndrome with constipation, and gastroesophageal reflux disease; and ATI-9242, an antipsychotic agent in Phase I clinical development for the treatment of schizophrenia and other psychiatric disorders. The company also involves in the preclinical development of ATI-20,000 and ATI-24,000, which focus on metabolic and gastrointestinal disorders.

Naturewell, Incorporated does not have significant operations. Naturewell company intends to seek business opportunities, including an acquisition or merger with an operating business. Previously, it engaged in the research and development of proprietary healthcare products for various conditions, which comprise primary migraine medication, MIGRASPRAY. Naturewell company is based in San Diego, California.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.